Annovis Bio Inc (ANVS)

$ANVS Maria has emphasized the subgroups and how it may impacted the effectiveness of Butanetap, or any other drug. Lot folks said that is BS. Well, today's article basically suggest BP agrees. However, BP will not own up to this because they are not the front runner in this catagory and they have nothing to gain.

$ANVS Great day! On Friday, December 12th, ANVS moved up 8.97% while volume shrunk to 0.5× the usual levels. Multiple bullish signals emerged — Crossed Above 20 DMA, Bullish Engulfing, New Uptrend & Directional Movement Crossover Bullish — suggesting potential strength ahead. Key support levels exist at 3.81, 3.49 & 3.28, with resistance at 4.34, 4.55 & 4.87.

Morning Red Turns Afternoon Green $COGT $STIM $VERA $ANVS stumbled out the gate but soared into the close. market warriors showing how to flip the script in style

$ANVS you are probably right. That’s why tech is down lately because the paid trolls are pushing false narratives like OpenAI is delaying data centers into 2028, which company management denied and Broadcom, which beat earnings estimates billed as not good enough by the analysts.

$ANVS is Hoffman buying today?

$ANVS holding 20 dma

$ANVS $AVXL Missling WOULD NEVER now that it’s officially rejected by EMA

$AVXL Like that $ANVS insiders bought shares. what have our insider done?

$ANVS Maria's quote below is so true. My fatherinlaws doc said that he had shaking left hand because of his old age..(doc = mamaluke) 2nd opinion doc..he found Parkinsons.

$ANVS anyone watching this ??

$ANVS Another bites it Europes EMA's Committee for Medicinal Products for Human Use (CHMP) recommended denying marketing approval for blarcamesine (Anavex 2-73) for early Alzheimer's, citing insufficient effectiveness/safety data and impurity issues.

$ANVS Algos picking up because of article or is it real buyers? 👀

$ANVS healthy consolidation on the middle Bollinger band. Noise always gets loud when retracing or in the trough⏳

$ANVS https://www.reuters.com/business/healthcare-pharmaceuticals/alzheimers-drug-hunt-learns-cancer-fights-multi-target-playbook-2025-12-12/"Annovis Bio (ANVS.N), opens new tab is developing a drug with multiple targets. Its experimental drug buntanetap, now in Phase 3 testing, targets amyloid, tau and two other neurotoxic proteins. Annovis CEO Maria Maccecchini said an earlier study failed because inadequate screening allowed for many participants who did not actually have Alzheimer's. "When we eliminated them by blood testing, then we got highly statistically significant cognitive improvement," she said. "We assume that doctors know what's Alzheimer's and Parkinson's... but maybe they don't."

$ANVS 2-3 yrs in Dagestan and we'll be fine xd

$ANVS https://cdn.prod.website-files.com/66b473381a97d1108ee4e2aa/693997f9b992da7907f5fad1_Annovis%20Corporate%20Presentation%20-%20December%202025%20.pdf

$ANVS I thought 5 was intermediate highest to pause rise and do a back-test with a falling wedge style with around 33% drawdown. It went to 5 from 2 so 33% drawdown is about -1.3 from 5... theoretically settling around 3.6-3.7...Hoping to form a good support before heading to 8.

An $ANVS conversation ... @wormy01 I am moved by this thread that @Rbrmd started and sorry to hear that @justateacher is also dealing with this in her family's life. I would have moved mountains to help Dr. Maccecchini get the 200M to 250M she said she needed to run her pivotal trials based on believing that her drug was actually going to help patients. Once inside her company I started to see how she actually runs things, how little she thinks of patients in my opinion, and all of the contractual and SEC violations she is so comfortable in breaking. The lack of funding is not because of whatever nefarious story she is projecting or that Big Pharma is not ready to think out of the box to accept her drug's supposed mechanism of action. From what I have seen and from the 4 plus years that I have supported her in various ways I can absolutely state ... just read the many comments that I have posted on this channel over the previous months. Dr. Maccecchini is not what she purports to be. She can challenge me and all the observations I have, backed with the evidence, in a Courtroom over this. If anyone reading this has or does suffer huge financial losses in the future, please reach out to me. Unifying the lawsuits to come will have huge benefits. Nothing in my opinion based on what I have seen will benefit patients beyond the effect of a placebo. While that feels good for patients and their families for those who experience this while on buntanetap, NO pharmaceutical or biotechnology company focused in this space will partner, back, or provide financial support for Annovis Bio in my opinion based on drug efficacy. Although highly unlikely, if any support does occur it will be based on some other benefit, but NOT based on drug efficacy. Whatever efficacy there is, if there is any, is being wildly over stated by Dr. Maccecchini. She is welcome to speak for herself as she does read Stocktwits and has commented on this channel in the past. Dr. Maccecchini, you are welcome to join this conversation @MaccM

$ANVS some people are bulls and some are bears, and that what make a market. I dont think Maria has intentionally mislead investors. She may have been overconfident due to her own conviction. Let it be and time will tell.

Enter: $ANVS Calls Strike Price: $4 Expiry Date: JAN 02 2026 Buy in Price: $0.55 - $5.00 Sell Price: $0.87 Profit : +59% (Turn every $1 into $1.59) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

It appears in one form or another that the CEO of $ANVS Dr. Maccecchini has convinced novice shareholders that the mysterious "dark side of Wall Street that the SEC ignores" is responsible for shareholders' suffering. (Image 1: Two posts from 5xStarTrader) Nothing could be farther from the truth. I know this because after being a loyal long-term investor and supporter since 2021 (like many of you), Dr. Maccecchini provided me her data to format in a way which would attract corporate support. It turns out that this is impossible IMO since she is a sloppy drug trial designer. I see some comments about Annovis Bio filing a cease and desist on today’s channel here. That would be an interesting dilemma. What things have I said about the company over the previous 100 post are untruth? Anything? (Image 4: C&D synopsis) But, first I want to understand why some investors think that the data is good? It is NOT which is one of the several reasons she doesn't have a true suitor. All the additional reasons are not good either. Is it because Dr. Maccecchini's repeated statement that she is “900% confident her drug works” sufficient for people ... despite the absence of hardly any robust evidence? Note: The evidence you think is robust ... isn't, IMO. It's only robust because Dr. Maccecchini tells you it is. No one else outside of her organization or anyone that isn't stuck with holding ANVS stock shares will agree with her. Why does Dr. Maccecchini feel that it is appropriate to attack authors who expose her bad data? (Image 2: DARVO 1) Why is there a need to blame entities who short her stock when it is her own poor work that Wall Street understands is very likely valueless? (Image 3: DARVO 2) Does she do so because she knows that novice investors will embrace this storyline and remain willingly blind to the truth about the efficacy, if any, of her drug? IMO, she is tugging at people’s heartstrings, their desire to help a loved one or invest in honor of one who has passed due to dementia, all while pitching the story of herself as the lone savior who will against all odds cure 20+ neurologic diseases!